**Immunization Test Tool Release Notes for Version 2.0.12 May 2, 2023**

**Data**

| **Test Case / Message Profile** | **Issue** | **Resolution** |
| --- | --- | --- |
| For Z22 messages | Per the CDC, the following **Unit of Sale NDC(**s) has/have been added:   * 00006-4293-02 for ERVEBO (Ebola Zaire vaccine, live, recombinant, 1mL dose) * 80631-0102-10 for COVID-19, subunit, rS-nanoparticle+Matrix-M1 Adjuvant, PF, 0.5 mL CARTON, 10 VIAL, MULTI-DOSE * 58160-0740-21 for rotavirus, live, monovalent vaccine (Rotarix)   Per the CDC, the following Unit of Sale NDC(s) has/have been added for **the** New Southern Hemisphere Influenza Vaccines for 2023 Season   * 49281-0323-50 for influenza, Southern Hemisphere, preservative free * 49281-0355-15 for influenza, Southern Hemisphere, quadrivalent, with preservative * 49281-0379-50 for influenza, Southern Hemisphere, high-dose, quadrivalent | Update(s) has/have been made to the **NDC Unit of Sale Value Set** in the Immunization Test Suite  Added:   * **Code**: 00006-4293-02 * **Code System**: NDC * **Description**: ERVEBO (Ebola Zaire vaccine, live, recombinant, 1mL dose) * **Code**: 80631-0102-10 * **Code System**: NDC * **Description**: COVID-19, subunit, rS-nanoparticle+Matrix-M1 Adjuvant, PF, 0.5 mL CARTON, 10 VIAL, MULTI-DOSE * **Code**: 58160-0740-21 * **Code System**: NDC * **Description**: rotavirus, live, monovalent vaccine (Rotarix) * **Code**: 49281-0323-50 * **Code System**: NDC * **Description**: influenza, Southern Hemisphere, preservative free * **Code**: 49281-0355-15 * **Code System**: NDC * **Description**: influenza, Southern Hemisphere, quadrivalent, with preservative * **Code**: 49281-0379-50 * **Code System**: NDC * **Description**: influenza, Southern Hemisphere, high-dose, quadrivalent |
| For Z22 messages | Per the CDC, the following **Unit of Use NDC(s)** has/have been added:   * 00006-4293-00 for ERVEBO (Ebola Zaire vaccine, live, recombinant, 1mL dose) * 80631-0102-01 for COVID-19, subunit, rS-nanoparticle+Matrix-M1 Adjuvant, PF, 0.5 mL VIAL, MULTI-DOSE, 2.5 mL * 58160-740-02 for rotavirus, live, monovalent vaccine (Rotarix)   Per the CDC, the following Unit of Use NDC(s) has/have been added for **the** New Southern Hemisphere Influenza Vaccines for 2023 Season   * 49281-0323-88 for influenza, Southern Hemisphere, preservative free * 49281-0355-78 for influenza, Southern Hemisphere, quadrivalent, with preservative * 49281-0379-88 for influenza, Southern Hemisphere, high-dose, quadrivalent | Update(s) has/have been made to the **NDC Unit of Use Value Set** in the Immunization Test Suite  Added:   * **Code**: 00006-4293-00 * **Code System**: NDC * **Description**: ERVEBO (Ebola Zaire vaccine, live, recombinant, 1mL dose) * **Code**: 80631-0102-01 * **Code System**: NDC * **Description**: COVID-19, subunit, rS-nanoparticle+Matrix-M1 Adjuvant, PF, 0.5 mL VIAL, MULTI-DOSE, 2.5 mL * **Code**: 58160-740-02 * **Code System**: NDC * **Description**: rotavirus, live, monovalent vaccine (Rotarix) * **Code**: 49281-0323-88 * **Code System**: NDC * **Description**: influenza, Southern Hemisphere, preservative free   **Code**:   * **Code**: 49281-0355-78 * **Code System**: NDC * **Description**: influenza, Southern Hemisphere, quadrivalent, with preservative * **Code**: 49281-0379-88 * **Code System**: NDC * **Description**: influenza, Southern Hemisphere, high-dose, quadrivalent |
| For Z22, Z32, and Z42 messages | Per the CDC, the following addition(s)/modification(s) has/have been made to the **CVX** table:  Added:   * **CVX code 231** for influenza, Southern Hemisphere, high-dose, quadrivalent   Added **New non-US CVX codes not considered to count towards immunity in the US:**   * **CVX code 521** for SARS-COV-2 (COVID-19) vaccine SP, protein-based, adjuvanted, B.1.351 strain (VidPrevtyn Beta), Sanofi-GSK   Modified Description:   * **CVX Code 197 description updated**   + “influenza, high-dose seasonal, quadrivalent, **.7mL** dose, preservative free”   changed to   * + “influenza, high-dose seasonal, quadrivalent, **0.7mL** dose, preservative free” * **CVX Code 203 description updated**   + “meningococcal polysaccharide (groups A, C, Y, W-135) tetanus toxoid conjugate vaccine **.5mL** dose, preservative free”   changed to   * + “meningococcal polysaccharide (groups A, C, Y, W-135) tetanus toxoid conjugate vaccine **0.5mL** dose, preservative free” * **CVX Code 205 description updated**   + “influenza, high-dose seasonal, quadrivalent, **.7mL** dose, preservative free”   changed to   * + “influenza, high-dose seasonal, quadrivalent, **0.7mL** dose, preservative free” * **CVX Code 56 description updated**   + “dengue fever”   changed to   * + “dengue fever vaccine, tetravalent” | Update(s) has/have been made to the **CVX** **Value Set** in the Immunization Test Suite  Added:   * **Code**:231 * **Code System**: CVX * **Description**: influenza, Southern Hemisphere, high-dose, quadrivalent * **Code**: 521 * **Code System**: CVX * **Description**: SARS-COV-2 (COVID-19) vaccine SP, protein-based, adjuvanted, B.1.351 strain (VidPrevtyn Beta), Sanofi-GSK   Description Modified:   * **Code**: 197 * **Code System**: CVX * **Description**: influenza, high-dose seasonal, quadrivalent, 0.7mL dose, preservative free * **Code**: 203 * **Code System**: CVX * **Description**: meningococcal polysaccharide (groups A, C, Y, W-135) tetanus toxoid conjugate vaccine 0.5mL dose, preservative free * **Code**: 205 * **Code System**: CVX * **Description**: influenza, high-dose seasonal, quadrivalent, 0.7mL dose, preservative free * **Code**: 56 * **Code System**: CVX * **Description**: dengue fever vaccine, tetravalent |
| For Z22, Z32, and Z42 messages | Per the CDC, the following CVX/VIS mapping addition(s) has/have been made:  Added:   * **CVX Code 230** has been mapped to VIS barcode string 253088698300051611220501 for the **COVID-19 Moderna EUA Recipient-Caregiver Fact Sheet - Pediatric 6mo to <6yrs** VIS | Update(s) has/have been made to the **PHVS\_VISVaccines\_IIS** **Value Set** in the Immunization Test Suite  Added:   * **Code**: 230 * **Code System**: CVX * **Description**: **COVID-19 Moderna EUA Recipient-Caregiver Fact Sheet - Pediatric 6mo to <6yrs** VIS |

| **Message Profile** | **Issue** | | **Resolution** |
| --- | --- | --- | --- |
| For Z22, Z32, Z42 messages | Per the CDC, the following VIS document(s) and VIS Code(s) has/have been added: | | The new VIS document(s) with **Description** and associated VIS **Code** has/have been added to the **PHVS\_VISBarcodes\_IIS Value Set** in the Immunization Test Suite |
|  | **Document Type Description (New)** | **VIS Fully-encoded Test String** |
|  | COVID-19 Pfizer BioNTech EUA Recipient-Caregiver Fact Sheet - all ages 6 months and older | 253088698300058511230401 |
|  | COVID-19 Moderna EUA Recipient-Caregiver Fact Sheet - all ages 6 months and older | 253088698300059211230401 |

**Specific Validation**

| **Issue** | **Resolution** |
| --- | --- |
| The COVID-19 Test Plan is very much out-of-date (does not include example messages for multiple boosters, etc.), and the current COVID-19 situation in the US (a COVID-19 vaccination just generates a typical immunization record) does not merit maintaining a separate Test Plan for COVID-19 in the NIST Immunization Test Suite. | The COVID-19 Test Plan has been deleted from the Context-based Validation in the Immunization Test Suite. |

**User Interface**

| **Issue** | **Resolution** |
| --- | --- |
| None |  |

**Core Functionality**

| **Issue** | **Resolution** |
| --- | --- |
|  |  |

**Documentation**

| **Issue** | **Resolution** |
| --- | --- |
| None |  |

**SOAP Functionality**

| **Test Case** | **Issue** | **Resolution** |
| --- | --- | --- |
| None |  |  |

**Improvements/Features**

|  |
| --- |
| None |

**Issues for a Future Release**

**ONC 2015 Test Plan**

| **Test Case/if Applicable** | **Issue** |
| --- | --- |
| All Test Steps with a VXU message | In a VXU Context-based message where there are multiple OBX segments for each Order Group, if an OBX segment has OBX-3.1 populated with the 69764-9 LOINC code and has OBX-5.1 populated with an incorrect VIS ID, the Test Tool issues an Error notification that indicates   * in the **Path** information the VXU Order Group (e.g., “VXU\_V04.ORDER[1]”) within which the OBX with the error is contained and * in the **Line #** information the line number listed in the Message Content window for the ORC segment in that Order Group. * In the **Description** information that an Error has been found due to there being no OBX segment where OBX-3.1 is populated with the 69764-9 LOINC code and OBX-5.1 is populated with [an expected VIS ID] within in this Order Group.   The Path, Line #, and Description information may or may not be meaningful enough for a Tester to determine which OBX segment contains the VIS ID error.  The Tool will be modified to make the Error notification more specific and meaningful. |
| Context-free Data Quality Assurance (DQA) function | The DQA tab in the Context-free / VXU Z22 function has been removed in order to update the capability. The Tool will be modified with an updated version.  (Demonstration of how DQA is intended to function has been deleted from the updated Tool Tutorial.) |